Cumberland Pharmaceuticals Stock Earnings Reports

Cumberland Pharmaceuticals reported Q1 2026 revenue of $9.1 million (a 5% increase excluding a prior one-time milestone), a GAAP net loss of ~$3.3 million and an adjusted loss of $1.9 million ($0.13/share). The company continues to generate positive operating cash flow ($387k). Key commercial updates include FDA expanded labeling for Caldolor (postoperative pain, including pediatric patients), initiation of national sales promotion for Talicia, FDA clearance of the Vaprisol manufacturing site enabling a planned relaunch this year, launch of a refreshed Sancuso website, and first shipments of Vibativ to China. Cumberland announced a transformational agreement to sell its U.S. branded commercial portfolio to Apotex for $100 million cash (subject to shareholder approval), plus $9 million for inventory, transition-services fees and a sales-tied milestone; management expects modest taxes due to a $30M tax basis in the assets and >$53M of NOL carryforwards. After close, Apotex will assume commercialization responsibilities and Cumberland will pivot to an R&D/development-focused company centered on its pipeline—chiefly ifetroban (a thromboxane receptor antagonist) which has Fast Track, orphan and rare pediatric designations in Duchenne muscular dystrophy, ongoing systemic sclerosis and idiopathic pulmonary fibrosis studies, and an extensive safety database (~1,400 dosed). Given the planned divestiture, Cumberland no longer targets double-digit revenue growth for 2026, but expects materially lower post-close operating expenses while maintaining clinical spend to advance late-stage programs.